Esperion Therapeutics (ESPR) Enterprise Value (2018 - 2025)
Historic Enterprise Value for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$92.4 million.
- Esperion Therapeutics' Enterprise Value rose 3611.88% to -$92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.4 million, marking a year-over-year increase of 3611.88%. This contributed to the annual value of -$144.8 million for FY2024, which is 7600.55% down from last year.
- As of Q3 2025, Esperion Therapeutics' Enterprise Value stood at -$92.4 million, which was up 3611.88% from -$86.1 million recorded in Q2 2025.
- Over the past 5 years, Esperion Therapeutics' Enterprise Value peaked at -$82.2 million during Q4 2023, and registered a low of -$259.3 million during Q4 2021.
- In the last 5 years, Esperion Therapeutics' Enterprise Value had a median value of -$162.3 million in 2023 and averaged -$160.9 million.
- As far as peak fluctuations go, Esperion Therapeutics' Enterprise Value tumbled by 8263.47% in 2022, and later skyrocketed by 5453.82% in 2025.
- Quarter analysis of 5 years shows Esperion Therapeutics' Enterprise Value stood at -$259.3 million in 2021, then surged by 35.66% to -$166.9 million in 2022, then surged by 50.71% to -$82.2 million in 2023, then plummeted by 76.01% to -$144.8 million in 2024, then skyrocketed by 36.14% to -$92.4 million in 2025.
- Its Enterprise Value was -$92.4 million in Q3 2025, compared to -$86.1 million in Q2 2025 and -$114.6 million in Q1 2025.